Exubera will be the first inhaled insulin to hit the Canadian market

October 2007

Exubera will be the first inhaled insulin to hit the Canadian market later this month.

It's an alternative to short-acting or regular insulin.

Exubera will be used in combination with a longer-acting insulin for type 1 diabetes. For type 2 diabetes, it will be used alone...or with oral hypoglycemics...or a longer-acting insulin.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

whether it's legal to dispense or prescribe against a contraindication or a bold or black box warning
Diabetes Exubera will be the first inhaled insulin to hit the Canadian market
Antithrombotics whether patients should undergo genetic testing to determine their warfarin dose
Cardiology blood pressure should be controlled before starting daily aspirin
Asthma New National Institutes of Health guidelines will improve asthma treatment
Infectious Diseases Health Canada will limit use of Ketek (telithromycin)
Infectious Diseases combining ceftriaxone (Rocephin) with calcium may cause death
Psychiatry whether it makes sense to use pregabalin and gabapentin TOGETHER for pain or seizures
Psychiatry Some people are abusing Seroquel (quetiapine)
Vaccines when to avoid live vaccines
Neurology & Pain Fentanyl patches (Duragesic, etc) are causing deaths
Dermatology whether a rash could be caused by a drug and what to do about it
Pediatrics about the best way to check for fever

Exubera will be the first inhaled insulin to hit the Canadian market

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents